2
Clinical Trials associated with IMM-2520A Phase 1 Clinical Study to Evaluate IMM2520 Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Patients With Advanced Solid Tumors
This is a multi-center, open-label, dose-escalation and cohort-expansion phase I clinical study to evaluate the safety and tolerability, pharmacokinetics profile, efficacy and immunogenicity of IMM2520 in subjects with advanced solid tumors.
[Translation] Phase I clinical study of IMM2520 in the treatment of advanced solid tumors
主要目的:
1.评估IMM2520治疗晚期实体瘤的安全性和耐受性
2.确定IMM2520治疗晚期实体瘤的最大耐受剂量(MTD)和2期临床推荐剂量(RP2D)
3.评估IMM2520治疗晚期实体瘤的临床疗效
次要目的:
1.评价IMM2520治疗晚期实体瘤的药代动力学(PK)特征
2.评估IMM2520人体的免疫原性
探索性目的:
1.探索生物标志物(包括,但不限于:程序细胞死亡蛋白配体-1[PD-L1]与CD47共表达、受体占位率[RO])与IMM2520的临床有效性的相关性
2.探索IMM2520的人体暴露量和疗效(E-R)的相关性
3探索IMM2520的群体药代动力学(pop-PK)的特征
[Translation] Primary objectives:
1. Evaluate the safety and tolerability of IMM2520 in the treatment of advanced solid tumors
2. Determine the maximum tolerated dose (MTD) and recommended dose (RP2D) of IMM2520 in the treatment of advanced solid tumors
3. Evaluate the clinical efficacy of IMM2520 in the treatment of advanced solid tumors
Secondary objectives:
1. Evaluate the pharmacokinetic (PK) characteristics of IMM2520 in the treatment of advanced solid tumors
2. Evaluate the immunogenicity of IMM2520 in humans
Exploratory objectives:
1. Explore the correlation between biomarkers (including, but not limited to: programmed cell death protein ligand-1 [PD-L1] and CD47 co-expression, receptor occupancy [RO]) and the clinical effectiveness of IMM2520
2. Explore the correlation between human exposure and efficacy (E-R) of IMM2520
3 Explore the characteristics of population pharmacokinetics (pop-PK) of IMM2520
100 Clinical Results associated with IMM-2520
100 Translational Medicine associated with IMM-2520
100 Patents (Medical) associated with IMM-2520
100 Deals associated with IMM-2520